EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Jennifer R Brown, Barbara Eichhorst, Peter Hillmen, Wojciech Jurczak, Maciej Kaźmierczak, Nicole Lamanna, Susan M O'Brien, Constantine S Tam, Lugui Qiu, Keshu Zhou, Martin Simkovic, Jiri Mayer und 16 weitere

New England Journal of Medicine · 26.01.2023 · 388 (4) · 319-332

DOI: 10.1056/nejmoa2211582 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 26.01.2023. Verfasst von Jennifer R Brown und 27 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, C…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Agents, Heart Diseases. Die Arbeit wurde bisher 493-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: BeiGene.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAntineoplastic AgentsHeart DiseasesHumansDisease ProgressionAdeninePiperidinesPyrazolesPyrimidines

Substanzen

Antineoplastic AgentsibrutinibAdeninePiperidineszanubrutinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); the Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Ge…

Förderung

  • BeiGene

Zitieren

APA

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O'Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., …, & Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319-332. https://doi.org/10.1056/nejmoa2211582

Vancouver

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine. 2023;388(4):319-332. doi:10.1056/nejmoa2211582

BibTeX
@article{Brown2023,
  author = {Brown, Jennifer R and Eichhorst, Barbara and Hillmen, Peter and Jurczak, Wojciech and Kaźmierczak, Maciej and Lamanna, Nicole and O'Brien, Susan M and Tam, Constantine S and Qiu, Lugui and Zhou, Keshu and Simkovic, Martin and Mayer, Jiri and Gillespie-Twardy, Amanda and Ferrajoli, Alessandra and Ganly, Peter S and Weinkove, Robert and Grosicki, Sebastian and Mital, Andrzej and Robak, Tadeusz and Osterborg, Anders and Yimer, Habte A and Salmi, Tommi and Wang, Megan-Der-Yu and Fu, Lina and Li, Jessica and Wu, Kenneth and Cohen, Aileen and Shadman, Mazyar},
  title = {Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {388},
  number = {4},
  pages = {319--332},
  doi = {10.1056/nejmoa2211582}
}
Kostenlos starten →